xGen^¢ç Acute Myeloid Leukemia Cancer Panel

The xGen AML Cancer Panel v1.0 comprises 11,743 xGen Lockdown^¢ç Probes, spanning 1.19 Mb of the human genome, for targeted enrichment of >260 genes associated with AML, to provide more efficient detection of disease-causing mutations.

• Obtain high coverage uniformity with 98% of genomic targets covered at greater than 0.2 x mean coverage
• Detect variations reliably with high reproducibility and increased depth of coverage
• Observe high relevance for AML-related applications due to empirically derived targets
• Enjoy fast turnaround via easy online ordering and next day shipping

xGen Acute Myeloid Leukemia Cancer Panel

The xGen Acute Myeloid Leukemia Cancer Panel v1.0 is comprised of individually synthesized and quality controlled xGen Lockdown Probes. The panel consists of 11,743 xGen Lockdown Probes targeting empirically derived regions within 260 genes. The targets were defined by whole genome and exome sequencing of 200 AML patients.

Panel composition (target genes)

Table 1. Frequently researched genes included in the xGen AML Cancer Panel.*

* The panel does not target every exon in each gene, but targets all regions found to be mutated in the TCGA study (N Engl J Med, 368(22):2059–2074). For a complete list of genes, click here.